<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115319</url>
  </required_header>
  <id_info>
    <org_study_id>SEP361-304</org_study_id>
    <secondary_id>2019-002259-40</secondary_id>
    <nct_id>NCT04115319</nct_id>
  </id_info>
  <brief_title>A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.</brief_title>
  <official_title>A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to evaluate the long-term safety and tolerability of an investigational drug
      in people with schizophrenia.

      This study is accepting male and female participants between 18 years old -65 years old who
      have been diagnosed with schizophrenia. This study will be conducted in approximately 50
      study centers worldwide. The study will last approximately 57 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study
      designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day)
      compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult subjects with
      schizophrenia. This study is projected to randomize a least 300 subjects to two treatment
      groups (SEP-363856 50 to 100 mg/day or quetiapine XR 400 to 800 mg/day) in a 2:1 ratio. Study
      drug will be taken once a day and may be taken without food or with a light meal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">March 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-blind, Active Comparator-Controlled Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>52 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP363856</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>quetiapine XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP363856</intervention_name>
    <description>SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule</description>
    <arm_group_label>SEP363856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine XR</intervention_name>
    <description>quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule</description>
    <arm_group_label>quetiapine XR</arm_group_label>
    <other_name>Seroquel XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        The main inclusion criteria include, but are not limited to the following:

          -  Male or female subject between 18 to 65 years of age (inclusive) at the time of
             consent.

          -  Subject meets DSM-5 criteria for a diagnosis of schizophrenia as established by
             clinical interview (using the DSM-5 as a reference and confirmed using the SCID-CT).
             The time since the subject's diagnosis must be ≥ 1 year prior to Screening.

          -  Subject must have a CGI-S score ≤ 4 at Screening and Baseline.

          -  Subject must have a PANSS total score ≤ 80 at Screening and Baseline.

          -  Subject is judged to be clinically stable (i.e., no evidence of an acute exacerbation)
             by the Investigator for at least 8 weeks prior to Screening.

          -  Subject has had no change in antipsychotic medication(s) (minor dose adjustments for
             tolerability purposes are permitted) for at least 6 weeks prior to Screening.

          -  Subjects taking an antipsychotic agent at Screening may participate in this study only
             if there are signs of intolerability or lack of efficacy of the current antipsychotic
             (as determined by the Investigator).

          -  Subject is, in the opinion of the Investigator, generally healthy based on Screening
             medical history, PE, neurological examination, vital signs, electrocardiogram (ECG)
             and clinical laboratory values (hematology, chemistry and urinalysis).

        Exclusion criteria:

        Main exclusion criteria include, but are not limited to:

          -  Subject was hospitalized for a psychiatric illness within the 8 weeks prior to
             Screening.

          -  Subject has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5
             diagnosis other than schizophrenia. Exclusionary disorders include but are not limited
             to alcohol use disorder (within past 12 months), substance (other than nicotine or
             caffeine) use disorder within past 12 months, major depressive disorder,
             schizoaffective disorder,bipolar I or II disorder, obsessive compulsive disorder, and
             posttraumatic stress disorder.Symptoms of mild to moderate mood dysphoria or anxiety
             are allowed so long as thesesymptoms are not the primary focus of treatment.

          -  Subject is judged to be resistant to antipsychotic treatment by the Investigator,
             based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year
             period prior to Screening, given at adequate dose as per labeling, for at least 4
             weeks.

          -  Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Item 4 (active suicidal ideation with
             some intent to act, without specific plan) or Item 5 (active suicidal ideation with
             specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one
             month) or at Baseline (i.e., since last visit).

          -  Subject is at significant risk of harming self or others based on Investigator's
             judgment.

          -  Subject has attempted suicide within 6 months prior to Screening.

          -  Subject has received treatment with a psychotropic medication or herbal supplement
             within 3 days or 5 half-lives (whichever is longer)

          -  Subject has been treated with quetiapine or quetiapine XR within the 6 weeks prior to
             Screening or has a history of inadequate response or intolerability to quetiapine or
             quetiapine XR.

          -  Subject has any clinically significant unstable medical condition or any clinically
             significant chronic disease that in the opinion of the Investigator, would limit the
             subject's ability to complete and/or participate in the study.

          -  Subject has any clinically significant abnormal laboratory value(s) at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
    <email>ClinicalTrialDisclosure@sunovion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morteza Marandi, MD</last_name>
      <phone>562-246-3800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Gamez, MD</last_name>
      <phone>510-444-2877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Excell Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Soefje, MD</last_name>
      <phone>760-758-2222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Chavez, MD</last_name>
      <phone>858-278-3647</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armen Goegjian, MD</last_name>
      <phone>717-799-7799</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rishi Kakar, MD</last_name>
      <phone>786-571-1971</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Hernandez, MD</last_name>
      <phone>305-456-3630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Davis, MD</last_name>
      <phone>404-255-6005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Center for Psychiatric Research</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantin Abuzatoaie, MD</last_name>
      <phone>847-230-3599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Lincolnwood</city>
        <state>Illinois</state>
        <zip>60712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Kim, MD</last_name>
      <phone>224-534-7332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana Clinical Research</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Seal, MD</last_name>
      <phone>318-797-8988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PsychCare Consultants Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohd Malik, MD</last_name>
      <phone>314-849-1853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dean-Yurie, Altea Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac, MD</last_name>
      <phone>702-527-7401</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krzsztof Wroblewi-Neurobehavioral Research Inc.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Brenner, MD</last_name>
      <phone>516-295-7230</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tyne Moeller-Synexus Clinical Research US Inc.</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aggy Vallanat</last_name>
      <phone>718-969-3005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, MD</last_name>
      <phone>585-241-9670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hope Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurian Abraham, MD</last_name>
      <phone>980-209-9784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Shishuka Malhorta</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shishuka Malhotra, MD</last_name>
      <phone>330-493-1118</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Arkhangelsk Regional Clinical Psychiatric Hospital&quot;</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163530</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anatoliy Bogdanov, MD</last_name>
      <phone>+7 818 266 94 40</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Institution of Healthcare &quot;Psychiatric Hospital named after P.P. Kashchenko&quot;</name>
      <address>
        <city>Leningrad</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Raspopov, MD</last_name>
      <phone>+7 812 251 93 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Budgetary Institution of Healthcare of Omsk region &quot;Clinical Psychiatric Hospital n.a. N.N. Solodovnikov&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Ivanova, MD</last_name>
      <phone>+7 381 221 85 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Public Institution of Healthcare &quot;Psychiatric Hospital of Saint Nikolai Chudotvorets&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Snedkov, MD</last_name>
      <phone>+7 812 714 76 35</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev&quot; MoH RF</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kotsiubinskii, MD</last_name>
      <phone>+7 812 670 02 40</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Lutova, MD</last_name>
      <phone>+7 812 670 02 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Institution of Healthcare &quot;City Psychoneurological Dispensary #5&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195176</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liubov Gluskina, MD</last_name>
      <phone>+7 911 256 89 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Institution of Healthcare &quot;Psychoneurological Dispensay No 1&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislava Savitskaya, MD</last_name>
      <phone>+78122462786</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;Smolensk State Medical University&quot; of the MoH of the RF leg add: 28, Krupskoi str, Smolensk, Smolensk region, 214019; act add: 46-a, Kirova str, Smolensk</name>
      <address>
        <city>Smolensk</city>
        <zip>214031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Okhapkin, MD</last_name>
      <phone>+7 910 785 80 01</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S St-Petersburg state budget institution Psychoneurological dispensary #10</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekaterina Smetannikova, MD</last_name>
      <phone>+78127142010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Stavropol territory &quot;Regional Specialization Psychiatry Hospital # 2&quot;</name>
      <address>
        <city>Stavropol</city>
        <zip>357034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Zolotarev, MD</last_name>
      <phone>+7 962 449 94 53</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Clinic Stolet&quot; 30, Derbyshevskiy lane, Tomsk, Tomsk region, 634009, Russia based on FSBSI &quot;Tomsk National Research Medical Center of Russian Academy of Sciences&quot;</name>
      <address>
        <city>Tomsk</city>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Agarkov, MD</last_name>
      <phone>+7 382 240 60 29</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of Yaroslavl region &quot;Yaroslavl Regional Clinical Psychiatric Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Grigorieva, MD</last_name>
      <phone>+7 4852 73 28 52</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Carpathian Regional Clinical Center of Mental Health of Ivano-Frankivsk Regional Council, Department of Neuroses and Edge Conditions/States #8</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myron Mulyk, MD</last_name>
      <phone>+380504331029</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Clinical, Social and Child Psychiatry</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerii Pidkorytov, MD</last_name>
      <phone>+380 57 725 58 79</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine, Unit of Emergency Psychiatry and Narcology</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Linskiy, MD</last_name>
      <phone>+38(097)3750254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv Clinical Hospital on Railway Transport #2 of Healthcare Center branch of JSC &quot;Ukrainian Railway&quot;, Consultative and Diagnostic Center of Policlinic</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateryna Kleban, MD</last_name>
      <phone>+38050 6729701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council, Female Department #11, Male Department #12</name>
      <address>
        <city>Smila</city>
        <zip>20708</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iryna Kosenkova, MD</last_name>
      <phone>+380661856122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Ternopil Regional Clinical Psychoneurological Hospital of Ternopil Regional Council, Department of Psychiatry #2 (male), Department of Psychiatry #6 (female), Ternopil I.Ya. Gorbachevskyi National Medical University of t</name>
      <address>
        <city>Ternopil</city>
        <zip>46027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Venger, MD</last_name>
      <phone>+38 0677565556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise Transcarpathian Regional Medical Center of Mental Health and Medicine of Addictions of Transcarpathian Regional Council, Department of Psychiatry</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Romaniv, MD</last_name>
      <phone>+38 050 999 79 71</phone>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study may be made available upon request via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available upon request within 12 months of posting the study results on ct.gov.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

